Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Trial Profile

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms DELIVER
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Sep 2018 Planned End Date changed from 25 Jun 2021 to 22 Jun 2021.
    • 04 Sep 2018 Planned primary completion date changed from 25 Jun 2021 to 22 Jun 2021.
    • 04 Sep 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top